NASDAQ:NBIX Neurocrine Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $97.48 -0.98 (-1.00%) (As of 06/30/2022 04:00 PM ET) Add Compare Share Today's Range$96.43▼$99.0350-Day Range$75.79▼$99.9352-Week Range$71.88▼$108.01Volume711,919 shsAverage Volume807,060 shsMarket Capitalization$9.32 billionP/E Ratio135.39Dividend YieldN/APrice Target$112.21 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Stock Forecast (MarketRank)Overall MarketRank™2.32 out of 5 starsMedical Sector273rd out of 1,433 stocksBiological Products, Except Diagnostic Industry42nd out of 217 stocksAnalyst Opinion: 2.2Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 - 2.2 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 9 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $112.21, Neurocrine Biosciences has a forecasted upside of 15.1% from its current price of $97.48.Amount of Analyst CoverageNeurocrine Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesNeurocrine Biosciences has received 917 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeurocrine Biosciences has received 213 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeurocrine Biosciences has received 81.15% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote “Outperform” if you believe NBIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,629,709.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions93.21% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 71.20% in the coming year, from $1.91 to $3.27 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 135.39, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 33.83.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 135.39, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 33.50.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 6.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neurocrine Biosciences (NASDAQ:NBIX)Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.Read More NBIX Stock News HeadlinesJune 16, 2022 | nasdaq.comNBIX Crosses Below Key Moving Average LevelJune 13, 2022 | finance.yahoo.comNeurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022June 9, 2022 | americanbankingnews.comEquities Analysts Offer Predictions for Neurocrine Biosciences, Inc.'s FY2023 Earnings (NASDAQ:NBIX)May 26, 2022 | nasdaq.comNeurocrine Biosciences (NBIX) Shares Cross Above 200 DMAMay 23, 2022 | nasdaq.comFirst Week of July 15th Options Trading For Neurocrine Biosciences (NBIX)May 23, 2022 | finance.yahoo.comNeurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022May 19, 2022 | benzinga.comNeurocrine Biosciences Earnings Perspective: Return On Capital EmployedMay 13, 2022 | seekingalpha.comNeurocrine Biosciences valbenazine gets FDA orphan drug status for Huntington diseaseMay 6, 2022 | seekingalpha.comNeurocrine Biosciences, Inc. 2022 Q1 - Results - Earnings Call PresentationMay 5, 2022 | fool.comNeurocrine Biosciences (NBIX) Q1 2022 Earnings Call TranscriptMay 4, 2022 | nasdaq.comNeurocrine Biosciences Becomes Oversold (NBIX)May 4, 2022 | seekingalpha.comNeurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2022 Results - Earnings Call TranscriptMay 4, 2022 | markets.businessinsider.comNeurocrine Biosciences Inc Q1 Profit Decreases, misses estimatesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees900Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today6/30/2022Next Earnings (Estimated)8/02/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$112.21 High Stock Price Forecast$154.00 Low Stock Price Forecast$76.00 Forecasted Upside/Downside+15.1%Consensus RatingHold Rating Score (0-4)2.47058823529412 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$0.72 Trailing P/E Ratio135.39 Forward P/E Ratio51.04 P/E GrowthN/ANet Income$89.60 million Net Margins5.91% Pretax Margin7.92% Return on Equity5.30% Return on Assets3.49% Debt Debt-to-Equity Ratio0.27 Current Ratio4.02 Quick Ratio3.90 Sales & Book Value Annual Sales$1.13 billion Price / Sales8.22 Cash Flow$1.23 per share Price / Cash Flow79.11 Book Value$14.48 per share Price / Book6.73Miscellaneous Outstanding Shares95,577,000Free Float91,372,000Market Cap$9.32 billion OptionableOptionable Beta0.70 Neurocrine Biosciences Frequently Asked Questions Should I buy or sell Neurocrine Biosciences stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Neurocrine Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NBIX, but not buy additional shares or sell existing shares. View analyst ratings for Neurocrine Biosciences or view top-rated stocks. What is Neurocrine Biosciences' stock price forecast for 2022? 17 brokers have issued twelve-month price objectives for Neurocrine Biosciences' stock. Their NBIX stock forecasts range from $76.00 to $154.00. On average, they expect Neurocrine Biosciences' stock price to reach $112.21 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price. View analysts' price targets for Neurocrine Biosciences or view top-rated stocks among Wall Street analysts. How has Neurocrine Biosciences' stock price performed in 2022? Neurocrine Biosciences' stock was trading at $85.17 at the beginning of 2022. Since then, NBIX stock has increased by 14.5% and is now trading at $97.48. View the best growth stocks for 2022 here. When is Neurocrine Biosciences' next earnings date? Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Neurocrine Biosciences. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Wednesday, May, 4th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by $0.19. The company had revenue of $310.60 million for the quarter, compared to the consensus estimate of $304.07 million. Neurocrine Biosciences had a net margin of 5.91% and a trailing twelve-month return on equity of 5.30%. The business's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.33 EPS. View Neurocrine Biosciences' earnings history. Who are Neurocrine Biosciences' key executives? Neurocrine Biosciences' management team includes the following people: Dr. Kevin C. Gorman Ph.D., CEO & Director (Age 64, Pay $1.58M)Mr. Matthew C. Abernethy, Chief Financial Officer (Age 42, Pay $906.76k) (LinkedIn Profile)Dr. Jude Onyia Ph.D., Chief Scientific Officer (Age 58, Pay $621.66k)Mr. Eric S. Benevich, Chief Commercial Officer (Age 57, Pay $805k) (LinkedIn Profile)Dr. Eiry Wyn Roberts, Chief Medical Officer (Age 58, Pay $925.46k)Dr. Dimitri E. Grigoriadis, Chief Research Officer (Age 64) (LinkedIn Profile)Jane Sorensen, Head of Investor RelationsMr. Darin M. Lippoldt, Chief Legal Officer & Corp. Sec. (Age 56) (LinkedIn Profile)Mr. Kyle W. Gano, Chief Bus. Devel. and Strategy Officer (Age 49) (LinkedIn Profile)Ms. Julie S. Cooke, Chief HR Officer (Age 56) (LinkedIn Profile) What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences CEO Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among Neurocrine Biosciences' employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Neurocrine Biosciences' key competitors? Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS). View all of NBIX's competitors. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Square (SQ) and Salesforce (CRM). What is Neurocrine Biosciences' stock symbol? Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX." How do I buy shares of Neurocrine Biosciences? Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neurocrine Biosciences' stock price today? One share of NBIX stock can currently be purchased for approximately $97.48. How much money does Neurocrine Biosciences make? Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $9.32 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.72 on an earnings per share basis. How many employees does Neurocrine Biosciences have? Neurocrine Biosciences employs 900 workers across the globe. How can I contact Neurocrine Biosciences? Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for Neurocrine Biosciences is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at [email protected], or via fax at 858-617-7602. This page (NASDAQ:NBIX) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
